Pulmonary Artery Hypertension/Embolism Nonhuman Primates Disease Model

Pulmonary arterial hypertension (PAH) and pulmonary embolism (PE) are serious cardiovascular disorders that affect the lungs. PAH is characterized by an increase in pulmonary arterial pressure, which can lead to right ventricular hypertrophy and dysfunction. PE occurs when a blood clot becomes lodged in an artery in the lung, blocking blood flow to the lung.

At Prisys Biotechnologies, we have developed a non-human primate (NHP) model of PE/PAH induced by GSPEA/Monocrotaline. Our standard study duration is 4-8 weeks, during which we measure clinical endpoints such as CT/eCT, ultrasound, respiratory rate, heart rate, and SpO2.

Our model closely mimics the human disease, with the same embolization mechanism and reversible/irreversible model. This allows us to accurately assess the efficacy and safety of potential therapies for PE/PAH.

In the GSPEA/Monocrotaline induced PE/PAH model, the animals are exposed to either GSPEA or monocrotaline to induce PE or PAH, respectively. The model is designed to mimic the human disease in terms of pathology and clinical features. CT/eCT and ultrasound are used to monitor the progression of the disease and evaluate the effects of interventions.

Respiratory rate, heart rate, and SpO2 are also monitored as indicators of respiratory and cardiovascular function. This model offers the opportunity to evaluate potential treatments for PE and PAH, as well as to better understand the underlying mechanisms of these diseases. Furthermore, the reversible/irreversible model allows for the assessment of long-term effects of treatments and the potential for disease remission.

Overall, the GSPEA/Monocrotaline induced PE/PAH model is a valuable tool for studying these complex cardiovascular disorders and developing novel therapeutic interventions.

Hot Tags: pulmonary artery hypertension/embolism nonhuman primates disease model, research, study, monkey, gene therapy, NHP Non Alcoholic Steatohepatitis NASH Model, nhp company, NHP DMPK pharmacology, Coagulation Hemostasis Nonhuman Primates, NHP monkey Disease Models, vaccine PK pharmacology